Novo Nordisk stock climbs following the announcement of its plans to advance amycretin, a dual GLP-1/amylin agonist for ...

Novo Nordisk’s shock decision to oust its chief executive has resulted in the Ozempic maker once again becoming Europe’s ...

LONDON (Reuters) -Drugmaker Novo Nordisk is once again Europe's largest company by market capitalisation, rising above German ...

Novo Nordisk jumps 5% as Parvus Asset Management builds a stake to sway CEO succession amid leadership shakeup and pipeline ...

Novo Nordisk (NVO) shares hit their highest level in over two months following a Financial Times report that activist hedge ...

The current health news highlights a series of dynamic events, including Parvus Asset Management's stake in Novo Nordisk, WHO ...

The brokerage forecasts Dr Reddy’s semaglutide revenues at $280 million in 2027, contributing about 18% of the company’s ...

And it’s never a bad time to re-read some of the team’s excellent, award-winning coverage on the company: Last week, key ...

Eli Lilly (NYSE: LLY) sells a broad range of medicines, from cancer and immunology drugs to treatments for migraine. Right ...

Financial Stability: Eli Lilly's balance sheet is more robust, with debt making up only 4% of equity, considerably less than ...

The drug candidate, trevogrumab, in combination with Novo Nordisk's popular obesity drug Wegovy, chemically known as semaglutide, helped patients preserve muscle and increase fat loss in patients, ...

French pharmaceutical group Sanofi announced this morning that it will acquire Massachusetts-based Blueprint Medicines ...